NEW YORK (GenomeWeb) – Foundation Medicine said today that the US Food and Drug Administration has granted Breakthrough Device designation to a new liquid biopsy assay the firm is developing, an expanded version of its existing FoundationACT assay.

Under the Breakthrough Device program, an expansion of the Expedited Access Pathways program, the FDA works with a test developer to reduce the time and cost from development to approval.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.